The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
The acquisition is for an enterprise value of Rs. 218 crores
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated
